Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial-Reference-Cited by-同舟云学术

Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial

Published:2018-11 Issue:6 Volume:17 Page:837-844
ISSN:1538-4721
Container-title:Brachytherapy
language:en
Short-container-title:Brachytherapy

Author:

Morris W. James,Pickles Tom,Keyes Mira

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology

Reference30 articles.

1. Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer;Morris;Cancer,2013

2. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals;Keyes;Int J Radiat Oncol Biol Phys,2014

3. Rectal toxicity and rectal dosimetry in low-dose-rate iodine-125 permanent prostate implants: A long-term study in 1006 patients;Keyes;Brachytherapy,2011

4. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer results study group;Grimm;BJU Int,2012

5. Permanent prostate brachytherapy preplanned technique: The modern Seattle method step-by-step and dosimetric outcomes;Sylvester;Brachytherapy,2009

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Recurrent Disease after Radiation Therapy for Patients Considering Local Salvage Therapy: Past vs. Contemporary Management;Cancers;2023-12-18

2. Biochemical outcome after curative treatment for localized prostate cancer with external beam radiotherapy: a cross-sectional study;ecancermedicalscience;2023-11-10

3. LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients;Urologic Oncology: Seminars and Original Investigations;2023-11

4. The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer;Prostate International;2023-09

5. Outcome comparison of radical prostatectomy versus seed brachytherapy for clinically localized prostate cancer using two biochemical recurrence definitions;BMC Surgery;2023-08-27